Search

Your search keyword '"Tao Zf"' showing total 66 results

Search Constraints

Start Over You searched for: Author "Tao Zf" Remove constraint Author: "Tao Zf"
66 results on '"Tao Zf"'

Search Results

3. BCL-X L -targeting antibody-drug conjugates are active in preclinical models and mitigate on-mechanism toxicity of small-molecule inhibitors.

4. Incidence and warning signs for complications of human brucellosis: a multi-center observational study from China.

5. Diagnostic Accuracy of Prenatal Fetal Ultrasound to Detect Cleft Palate in High-Risk Fetuses: A Systematic Review and Meta-Analysis.

6. Expanding the Repertoire for "Large Small Molecules": Prodrug ABBV-167 Efficiently Converts to Venetoclax with Reduced Food Effect in Healthy Volunteers.

7. Structure-Based Design of A-1293102, a Potent and Selective BCL-X L Inhibitor.

8. Discovery of A-1331852, a First-in-Class, Potent, and Orally-Bioavailable BCL-X L Inhibitor.

9. [Clinical characteristics of human recombination activating gene 1 mutations in 8 immunodeficiency patients with diverse phenotypes].

10. [Analyses of clinicopathologic factors affecting neck control after postoperative radiation as adjuvant treatment for lymph node metastasis in head and neck squamous cell carcinoma].

12. lncRNA-MIAT regulates microvascular dysfunction by functioning as a competing endogenous RNA.

13. Exploiting selective BCL-2 family inhibitors to dissect cell survival dependencies and define improved strategies for cancer therapy.

14. Structure-guided design of a series of MCL-1 inhibitors with high affinity and selectivity.

15. Discovery of a Potent and Selective BCL-XL Inhibitor with in Vivo Activity.

16. Epigenetics and ocular diseases: from basic biology to clinical study.

17. Structure-Guided Rescaffolding of Selective Antagonists of BCL-XL.

18. Aberrant expression of long noncoding RNAs in early diabetic retinopathy.

19. Regulation of autophagy by high glucose in human retinal pigment epithelium.

21. Epigallocatechin-gallate (EGCG) regulates autophagy in human retinal pigment epithelial cells: a potential role for reducing UVB light-induced retinal damage.

22. Value of postoperative radiation therapy for regional control after dissection in head and neck squamous cell carcinoma cases.

23. Overexpression of synoviolin facilitates the formation of a functional synovial biomembrane.

24. [Preliminary report of laryngeal preservation in the surgical salvage of recurrent laryngeal cancer].

25. Changes of synaptic ultrastructure in the guinea pig interpositus nuclei associate with response magnitude and timing after trace eyeblink conditioning.

26. [Expression and role of soluble epoxide hydrolase in renal tissue of two kidneys one clip hypertension rats model].

27. [Outcomes of salvage laryngectomy after initial radiation failure in laryngeal squamous cell carcinoma].

28. The electromagnetic-trait imaging computation of traveling wave method in breast tumor microwave sensor system.

29. Discovery of 3H-benzo[4,5]thieno[3,2-d]pyrimidin-4-ones as potent, highly selective, and orally bioavailable inhibitors of the human protooncogene proviral insertion site in moloney murine leukemia virus (PIM) kinases.

30. [Investigations on salvage surgery-related problems for stomal recurrence after total laryngectomy].

31. Cyclin B1 is an efficacy-predicting biomarker for Chk1 inhibitors.

32. [Seasonal fluctuation of soil microbial biomass carbon in secondary oak forest and Pinus taeda plantation in north subtropical area of China].

33. Synthesis and in-vitro biological activity of macrocyclic urea Chk1 inhibitors.

34. Macrocyclic ureas as potent and selective Chk1 inhibitors: an improved synthesis, kinome profiling, structure-activity relationships, and preliminary pharmacokinetics.

35. Discovery of 4'-(1,4-dihydro-indeno[1,2-c]pyrazol-3-yl)-benzonitriles and 4'-(1,4-dihydro-indeno[1,2-c]pyrazol-3-yl)-pyridine-2'-carbonitriles as potent checkpoint kinase 1 (Chk1) inhibitors.

36. Cyanopyridyl containing 1,4-dihydroindeno[1,2-c]pyrazoles as potent checkpoint kinase 1 inhibitors: improving oral biovailability.

37. Prognostic factors and staging systems of multiple myeloma:.

38. Design, synthesis, and biological activity of 5,10-dihydro-dibenzo[b,e][1,4]diazepin-11-one-based potent and selective Chk-1 inhibitors.

39. Synthesis and biological evaluation of 4'-(6,7-disubstituted-2,4-dihydro-indeno[1,2-c]pyrazol-3-yl)-biphenyl-4-ol as potent Chk1 inhibitors.

40. 1,4-Dihydroindeno[1,2-c]pyrazoles as potent checkpoint kinase 1 inhibitors: extended exploration on phenyl ring substitutions and preliminary ADME/PK studies.

41. [Multi-modalities for reconstruction of circumferential defects in the pharyngoesophageal region].

42. Structure-based design, synthesis, and biological evaluation of potent and selective macrocyclic checkpoint kinase 1 inhibitors.

43. Selective Chk1 inhibitors differentially sensitize p53-deficient cancer cells to cancer therapeutics.

44. An efficient mammalian transfer RNA target for bleomycin.

45. Chk1 inhibitors for novel cancer treatment.

46. Synthesis and biological evaluation of 1-(2,4,5-trisubstituted phenyl)-3-(5-cyanopyrazin-2-yl)ureas as potent Chk1 kinase inhibitors.

47. [Prognostic analysis and assessment on the clinical staging systems of multiple myeloma--a report of 206 cases].

48. Solid-phase synthesis and biochemical evaluation of conformationally constrained analogues of deglycobleomycin A5.

49. Conformationally constrained analogues of bleomycin A5.

50. Sequence specificity, reactivity, and antitumor activity of DNA-alkylating pyrrole-imidazole diamides.

Catalog

Books, media, physical & digital resources